Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Novo Nordisk's next-gen obesity drug, CagriSema, faces trial challenges with dosage flexibility and trial length as side-effects remain controlled. Investor skepticism arose from weaker-than-expected ...

The company predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.

While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating ...

Find insight on Novo Nordisk, GSK and more in the latest Market Talks covering Health Care.